Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHST BioHarvest Sciences	$9.32 +1.1%	$7.41	$4.66 ▼ $9.90	$151.40M	0.68	15,467 shs	74,866 shs
CLLS Cellectis	$2.85 -0.3%	$1.98	$1.10 ▼ $3.24	$158.97M	3.03	286,754 shs	102,837 shs
CTOR Citius Oncology	$1.69 -1.7%	$2.43	$0.55 ▼ $6.19	$134.80M	3	1.55 million shs	59,776 shs
OVID Ovid Therapeutics	$0.97 +15.4%	$0.45	$0.24 ▼ $1.47	$59.75M	0.2	1.70 million shs	4.53 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHST BioHarvest Sciences	+1.08%	+6.39%	+32.20%	+43.38%	+931,999,900.00%
CLLS Cellectis	-0.35%	+9.62%	+43.22%	+80.38%	+41.09%
CTOR Citius Oncology	-1.74%	-6.63%	+7.64%	+84.70%	-31.58%
OVID Ovid Therapeutics	+15.43%	+88.39%	+148.72%	+220.13%	-3.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CLLS Cellectis	3.4442 of 5 stars	3.5	5.0	0.0	0.0	3.5	2.5	0.0
CTOR Citius Oncology	1.6599 of 5 stars	3.0	0.0	0.0	0.0	2.8	1.7	0.0
OVID Ovid Therapeutics	4.2447 of 5 stars	3.6	3.0	0.0	4.6	2.5	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHST BioHarvest Sciences	3.00	Buy	$13.67	46.64% Upside
CLLS Cellectis	3.00	Buy	$4.00	40.35% Upside
CTOR Citius Oncology	2.00	Hold	$3.00	77.51% Upside
OVID Ovid Therapeutics	3.17	Buy	$3.10	219.59% Upside

Current Analyst Ratings Breakdown

Latest OVID, CLLS, BHST, and CTOR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	OVID Ovid Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
5/27/2025	OVID Ovid Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$2.00 ➝ $1.50
5/23/2025	CTOR Citius Oncology	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
5/23/2025	CTOR Citius Oncology	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHST BioHarvest Sciences	$25.19M	6.08	N/A	N/A	($0.26) per share	-35.85
CLLS Cellectis	$56.30M	2.81	N/A	N/A	$1.75 per share	1.63
CTOR Citius Oncology	N/A	N/A	N/A	N/A	$0.41 per share	N/A
OVID Ovid Therapeutics	$6.65M	10.37	N/A	N/A	$0.78 per share	1.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHST BioHarvest Sciences	-$12.91M	-$0.70	N/A	N/A	N/A	-39.95%	-11,357.84%	-39.94%	N/A
CLLS Cellectis	-$36.76M	-$0.82	N/A	N/A	N/A	-100.69%	-68.05%	-21.53%	11/3/2025 (Estimated)
CTOR Citius Oncology	N/A	N/A	0.00	∞	N/A	N/A	-51.93%	-22.17%	N/A
OVID Ovid Therapeutics	-$26.43M	-$0.53	N/A	N/A	N/A	-574.44%	-58.87%	-43.18%	N/A

Latest OVID, CLLS, BHST, and CTOR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	OVID Ovid Therapeutics	-$0.16	-$0.06	+$0.10	-$0.06	$0.09 million	$6.27 million
8/11/2025	Q2 2025	BHST BioHarvest Sciences	-$0.1075	-$0.15	-$0.0425	-$0.24	$8.53 million	$8.52 million
8/4/2025	Q2 2025	CLLS Cellectis	-$0.15	-$0.24	-$0.09	-$0.24	$10.07 million	$18.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A
CLLS Cellectis	N/A	N/A	N/A	N/A	N/A
CTOR Citius Oncology	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHST BioHarvest Sciences	N/A	0.60	0.30
CLLS Cellectis	0.58	1.38	1.38
CTOR Citius Oncology	0.12	0.35	0.05
OVID Ovid Therapeutics	0.22	4.93	4.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHST BioHarvest Sciences	N/A
CLLS Cellectis	63.90%
CTOR Citius Oncology	70.52%
OVID Ovid Therapeutics	72.24%

Insider Ownership

Company	Insider Ownership
BHST BioHarvest Sciences	N/A
CLLS Cellectis	16.41%
CTOR Citius Oncology	4.57%
OVID Ovid Therapeutics	13.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHST BioHarvest Sciences	N/A	16.42 million	N/A	N/A
CLLS Cellectis	290	55.58 million	46.46 million	Optionable
CTOR Citius Oncology	N/A	78.37 million	74.79 million	N/A
OVID Ovid Therapeutics	60	71.11 million	61.80 million	Optionable

OVID, CLLS, BHST, and CTOR Headlines

Recent News About These Companies

Ovid Therapeutics Second Quarter 2025 Earnings: Beats Expectations

August 16 at 2:39 AM | finance.yahoo.com

Brokerages Set Ovid Therapeutics (NASDAQ:OVID) PT at $3.10

August 16 at 2:13 AM | americanbankingnews.com

Ovid Therapeutics Reports Increased Revenue Amid Challenges

August 14 at 11:49 AM | msn.com

Ovid Therapeutics Navigates FDA Disruptions and Government Challenges

August 14 at 2:05 AM | tipranks.com

Ovid Therapeutics: Strategic Advances and Promising Developments Justify Buy Rating

August 13 at 2:32 PM | tipranks.com

Ovid Therapeutics initiated with a Buy at Lucid Capital

August 13 at 1:08 PM | msn.com

Ovid Therapeutics Transfers Stock to Nasdaq Capital Market

August 13 at 1:08 PM | msn.com

Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates

August 13 at 10:26 AM | zacks.com

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

August 13 at 8:00 AM | globenewswire.com

Lucid Capital Markets initiates Ovid Therapeutics stock with Buy rating

August 13 at 7:13 AM | investing.com

Amit Rakhit: Global Access, Local Wisdom — How Biotech Thrives Amid Regulatory Complexity

August 13 at 3:06 AM | msn.com

Ovid Therapeutics (OVID) Projected to Post Quarterly Earnings on Tuesday

August 11, 2025 | americanbankingnews.com

B.Riley assumes coverage on Ovid Therapeutics stock with Buy rating

August 8, 2025 | investing.com

Ovid Therapeutics Sells Ganaxolone Royalty Rights for $7M to Immedica Pharma

July 25, 2025 | insidermonkey.com

Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference

July 23, 2025 | globenewswire.com

Ovid Therapeutics management to meet with B. Riley

July 17, 2025 | msn.com

Ovid woman arrested in Waterloo for driving with suspended license

July 16, 2025 | fingerlakes1.comF

Ovid Therapeutics Approves Key Proposals at Annual Meeting

July 10, 2025 | tipranks.com

Ovid Therapeutics Inc. (OVID) - Yahoo Finance

July 8, 2025 | finance.yahoo.com

Ovid Therapeutics Inc Chart - Morningstar

July 2, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

OVID, CLLS, BHST, and CTOR Company Descriptions

BioHarvest Sciences NASDAQ:BHST

$9.32 +0.10 (+1.08%)

As of 08/15/2025 03:45 PM Eastern

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.

Cellectis NASDAQ:CLLS

$2.85 -0.01 (-0.35%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.84 -0.01 (-0.35%)

As of 08/15/2025 06:25 PM Eastern

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Citius Oncology NASDAQ:CTOR

$1.69 -0.03 (-1.74%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.72 +0.03 (+1.48%)

As of 08/15/2025 07:53 PM Eastern

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Ovid Therapeutics NASDAQ:OVID

$0.97 +0.13 (+15.43%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$0.97 +0.00 (+0.41%)

As of 08/15/2025 07:59 PM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time